Press releases

Release
29.09.2017

Consolidated results for the first half of 2017

Download
Release
20.09.2017

International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board

Download
Release
07.09.2017

Pascal SIRVENT appointed Director of Discovery and Preclinical Research

Download
Release
05.09.2017

VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®

Download
Release
09.06.2017

Results of Phase I/II clinical study on the active ingredient of Valedia®

Download
Release
09.06.2017

VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, TOTUM-63, during the 77th Scientific Sessions of the American Diabetes Association.

Download
Release
02.06.2017

VALBIOTIS Initial Public Offering records huge success

Download
Release
24.04.2017

Sébastien PELTIER, CEO of VALBIOTIS, presents his vision of diabetes-free world at l’Echappée Volée

Download
Release
12.04.2017

Two partnership agreements to assess the effects of TOTUM-63, the active ingredient Valedia®, on intestinal microbiota

Download